Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
John F. Crowley's Annual Letter to BIO Membership
Dear Colleagues,  I am just past the two-year mark as BIO’s President & CEO, which arrives as we find ourselves at a defining moment for the future of biotechnology. For fifty years, our industry has delivered one of the great…
Learn more
BIO Comments on Global Benchmark for Efficient…
Learn more
BIO Comments on Guarding U.S. Medicare Against…
Learn more
All Letters, Testimony & Comments
  • Show All
Search
Results
Sarbanes-Oxley in Financial Services Compromise: Sarbanes-Oxley 404(b) Legislative Text in the Wall Street Reform and Consumer Protection Act of 2009
March 10, 2016
BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies.
Sarbanes Oxley 404(b) recommendations made by the 2009 Government-Business Forum on Small Business Capital Formation
March 10, 2016
The 2009 Government-Business Forum on Small Business Capital Formation recommended a permanent exemption for small companies from Section 404(b) of Sarbanes-Oxley. Additionally, they recommended that the SEC increase the public float threshold for…
Pilot Circuit Breaker Proposal: SEC issues proposal on pilot circuit breaker program to combat abusive short selling
March 10, 2016
BIO commends the SEC on its pilot circuit breaker proposal and urges the use of biotech companies in such proposal
IFRS Roadmap: SEC requests comments on U.S. conversion to a set of global accounting standards
March 10, 2016
BIO provides comment letter to SEC generally supporting the IFRS roadmap while maintaining safeguards for emerging companies during transition.
Letter to the Honorable John Carey
March 10, 2016
Letter to the Honorable John Carey, Chairman of the Senate Committee on Finance and Financial Institutions in Ohio from BIO, regarding House Bill 66.
Questions for the District of Columbia Board of Pharmacy for the drafting of SafeRx
March 10, 2016
Frequently Asked Questions Document
Letter to Governor Deval Patrick
March 10, 2016
BIO letter to Governor Deval Patrick of Massachusetts regarding concerns about Senate Bill 2863.
BIO Testimony regarding Oregan Senate Bill 570
March 10, 2016
Testimony to the Oregon Senate Environment & Land Use Committee regarding The Oregon Genetically Engineered Pharmaceutical and Industrial Crop Act.
Clinical Trials: ICTRP guidelines
March 10, 2016
BIO urges the ICTRP to focus on developing a procedure that would address the need to balance the incentive to innovate with the need to provide patients and health care providers with the information they need in order to assess the availability…
Clinical Trials: Review of the Declaration of Helsinki
March 10, 2016
BIO’s comments on the World Medical Association’s (WMA’s) Declaration of Helsinki.